Adaptation of controlled attenuation parameter

The controlled attenuation parameter (CAP) using FibroScan (Echosens, Paris, France) M or XL probe has been developed for liver steatosis assessment. However, CAP performs poorly in patients with high body mass index. The aim of our study was to assess whether CAP is overestimated using the standard...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2019-05, Vol.14 (5), p.e0217093
Hauptverfasser: Somda, Sosthene, Lebrun, Amandine, Tranchart, Hadrien, Lamouri, Karima, Prevot, Sophie, Njike-Nakseu, Micheline, Gaillard, Martin, Lainas, Panagiotis, Balian, Axel, Dagher, Ibrahim, Perlemuter, Gabriel, Naveau, Sylvie, Voican, Cosmin Sebastian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 5
container_start_page e0217093
container_title PloS one
container_volume 14
creator Somda, Sosthene
Lebrun, Amandine
Tranchart, Hadrien
Lamouri, Karima
Prevot, Sophie
Njike-Nakseu, Micheline
Gaillard, Martin
Lainas, Panagiotis
Balian, Axel
Dagher, Ibrahim
Perlemuter, Gabriel
Naveau, Sylvie
Voican, Cosmin Sebastian
description The controlled attenuation parameter (CAP) using FibroScan (Echosens, Paris, France) M or XL probe has been developed for liver steatosis assessment. However, CAP performs poorly in patients with high body mass index. The aim of our study was to assess whether CAP is overestimated using the standard XL probe in patients with morbid obesity, and in the case of an overestimation, to reprocess the data at a greater depth to obtain the appropriate CAP (CAPa). We conducted an observational prospective cohort study on a total of 249 severely obese patients admitted to our institution to undergo sleeve gastrectomy. Patients had a liver biopsy performed during the surgery and a CAP measurement during the 15 days preceding biopsy. Patient files were reprocessed retrospectively by an algorithm, blinded to the patients' clinical data. The algorithm automatically assessed the probe-to-capsula distance (PCD) by analysing the echogenicity of ultrasound signals on the time-motion mode. In the case of a distance >35 mm, the algorithm automatically selected a deeper measurement for CAP (CAPa). When PCD was less than 35 mm, the measured CAP was considered as appropriated (CAPa) and no further reprocessing was performed. CAP recording was not performed at a sufficient depth in 130 patients. In these patients, the CAPa obtained at the adapted depth was significantly lower than CAP (298±3.9 versus 340±4.2 dB/m; p 35 mm, steatosis stage was the only parameter independently correlated with CAP values. For the diagnosis of steatosis (S[greater than or equal to]1), moderate to severe steatosis (S[greater than or equal to]2) and severe steatosis (S = 3), the AUROC curves of CAPa (measured CAP in patients with PCD35 mm) were 0.86, 0.83 and 0.79, respectively. The Obuchowski measure for the diagnosis of steatosis was 0.90±0.013. CAP was overestimated in a half of morbidly obese patients using an XL probe, but CAP can be performed correctly in these patients after adapting the measurement depth.
doi_str_mv 10.1371/journal.pone.0217093
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_incontextgauss_ISR_A586555312</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A586555312</galeid><sourcerecordid>A586555312</sourcerecordid><originalsourceid>FETCH-LOGICAL-g992-17a178437da3e0921efe6cbad413d031a3615bcad4103312b18ef083e7e8fb153</originalsourceid><addsrcrecordid>eNqFj0FLw0AQhRdRsFb_gYecBA-JO5lusjmGorVQKGjxGibJJG1ZsyW7AX--hnqIJ0_vDe-bYZ4Q9yAjwBSejnboOzLRyXYcyRhSmeGFmEGGcZjEEi8n_lrcOHeUUqFOkpmI8ppOnvzBdoFtgsp2vrfGcB2Q99wN5-REPX2y5_5WXDVkHN_96lzsXp53y9dws12tl_kmbLMsDiElSPUC05qQZRYDN5xUJdULwFoiECagymqcJSLEJWhupEZOWTclKJyLx_PZlgwXh258i798S4Nzxfr9rciVTpRSP7v_sNuPv-zDhN0zGb931gxjSTcFvwGCAmQl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adaptation of controlled attenuation parameter</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Somda, Sosthene ; Lebrun, Amandine ; Tranchart, Hadrien ; Lamouri, Karima ; Prevot, Sophie ; Njike-Nakseu, Micheline ; Gaillard, Martin ; Lainas, Panagiotis ; Balian, Axel ; Dagher, Ibrahim ; Perlemuter, Gabriel ; Naveau, Sylvie ; Voican, Cosmin Sebastian</creator><creatorcontrib>Somda, Sosthene ; Lebrun, Amandine ; Tranchart, Hadrien ; Lamouri, Karima ; Prevot, Sophie ; Njike-Nakseu, Micheline ; Gaillard, Martin ; Lainas, Panagiotis ; Balian, Axel ; Dagher, Ibrahim ; Perlemuter, Gabriel ; Naveau, Sylvie ; Voican, Cosmin Sebastian</creatorcontrib><description>The controlled attenuation parameter (CAP) using FibroScan (Echosens, Paris, France) M or XL probe has been developed for liver steatosis assessment. However, CAP performs poorly in patients with high body mass index. The aim of our study was to assess whether CAP is overestimated using the standard XL probe in patients with morbid obesity, and in the case of an overestimation, to reprocess the data at a greater depth to obtain the appropriate CAP (CAPa). We conducted an observational prospective cohort study on a total of 249 severely obese patients admitted to our institution to undergo sleeve gastrectomy. Patients had a liver biopsy performed during the surgery and a CAP measurement during the 15 days preceding biopsy. Patient files were reprocessed retrospectively by an algorithm, blinded to the patients' clinical data. The algorithm automatically assessed the probe-to-capsula distance (PCD) by analysing the echogenicity of ultrasound signals on the time-motion mode. In the case of a distance &gt;35 mm, the algorithm automatically selected a deeper measurement for CAP (CAPa). When PCD was less than 35 mm, the measured CAP was considered as appropriated (CAPa) and no further reprocessing was performed. CAP recording was not performed at a sufficient depth in 130 patients. In these patients, the CAPa obtained at the adapted depth was significantly lower than CAP (298±3.9 versus 340±4.2 dB/m; p 35 mm, steatosis stage was the only parameter independently correlated with CAP values. For the diagnosis of steatosis (S[greater than or equal to]1), moderate to severe steatosis (S[greater than or equal to]2) and severe steatosis (S = 3), the AUROC curves of CAPa (measured CAP in patients with PCD35 mm) were 0.86, 0.83 and 0.79, respectively. The Obuchowski measure for the diagnosis of steatosis was 0.90±0.013. CAP was overestimated in a half of morbidly obese patients using an XL probe, but CAP can be performed correctly in these patients after adapting the measurement depth.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0217093</identifier><language>eng</language><publisher>Public Library of Science</publisher><subject>Algorithms ; Analysis ; Bariatric surgery ; Body mass index ; Diagnosis ; Fatty liver ; Health aspects ; Liver ; Obesity ; Overweight persons ; Prevalence studies (Epidemiology) ; Risk factors ; Surgery</subject><ispartof>PloS one, 2019-05, Vol.14 (5), p.e0217093</ispartof><rights>COPYRIGHT 2019 Public Library of Science</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27922,27923</link.rule.ids></links><search><creatorcontrib>Somda, Sosthene</creatorcontrib><creatorcontrib>Lebrun, Amandine</creatorcontrib><creatorcontrib>Tranchart, Hadrien</creatorcontrib><creatorcontrib>Lamouri, Karima</creatorcontrib><creatorcontrib>Prevot, Sophie</creatorcontrib><creatorcontrib>Njike-Nakseu, Micheline</creatorcontrib><creatorcontrib>Gaillard, Martin</creatorcontrib><creatorcontrib>Lainas, Panagiotis</creatorcontrib><creatorcontrib>Balian, Axel</creatorcontrib><creatorcontrib>Dagher, Ibrahim</creatorcontrib><creatorcontrib>Perlemuter, Gabriel</creatorcontrib><creatorcontrib>Naveau, Sylvie</creatorcontrib><creatorcontrib>Voican, Cosmin Sebastian</creatorcontrib><title>Adaptation of controlled attenuation parameter</title><title>PloS one</title><description>The controlled attenuation parameter (CAP) using FibroScan (Echosens, Paris, France) M or XL probe has been developed for liver steatosis assessment. However, CAP performs poorly in patients with high body mass index. The aim of our study was to assess whether CAP is overestimated using the standard XL probe in patients with morbid obesity, and in the case of an overestimation, to reprocess the data at a greater depth to obtain the appropriate CAP (CAPa). We conducted an observational prospective cohort study on a total of 249 severely obese patients admitted to our institution to undergo sleeve gastrectomy. Patients had a liver biopsy performed during the surgery and a CAP measurement during the 15 days preceding biopsy. Patient files were reprocessed retrospectively by an algorithm, blinded to the patients' clinical data. The algorithm automatically assessed the probe-to-capsula distance (PCD) by analysing the echogenicity of ultrasound signals on the time-motion mode. In the case of a distance &gt;35 mm, the algorithm automatically selected a deeper measurement for CAP (CAPa). When PCD was less than 35 mm, the measured CAP was considered as appropriated (CAPa) and no further reprocessing was performed. CAP recording was not performed at a sufficient depth in 130 patients. In these patients, the CAPa obtained at the adapted depth was significantly lower than CAP (298±3.9 versus 340±4.2 dB/m; p 35 mm, steatosis stage was the only parameter independently correlated with CAP values. For the diagnosis of steatosis (S[greater than or equal to]1), moderate to severe steatosis (S[greater than or equal to]2) and severe steatosis (S = 3), the AUROC curves of CAPa (measured CAP in patients with PCD35 mm) were 0.86, 0.83 and 0.79, respectively. The Obuchowski measure for the diagnosis of steatosis was 0.90±0.013. CAP was overestimated in a half of morbidly obese patients using an XL probe, but CAP can be performed correctly in these patients after adapting the measurement depth.</description><subject>Algorithms</subject><subject>Analysis</subject><subject>Bariatric surgery</subject><subject>Body mass index</subject><subject>Diagnosis</subject><subject>Fatty liver</subject><subject>Health aspects</subject><subject>Liver</subject><subject>Obesity</subject><subject>Overweight persons</subject><subject>Prevalence studies (Epidemiology)</subject><subject>Risk factors</subject><subject>Surgery</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFj0FLw0AQhRdRsFb_gYecBA-JO5lusjmGorVQKGjxGibJJG1ZsyW7AX--hnqIJ0_vDe-bYZ4Q9yAjwBSejnboOzLRyXYcyRhSmeGFmEGGcZjEEi8n_lrcOHeUUqFOkpmI8ppOnvzBdoFtgsp2vrfGcB2Q99wN5-REPX2y5_5WXDVkHN_96lzsXp53y9dws12tl_kmbLMsDiElSPUC05qQZRYDN5xUJdULwFoiECagymqcJSLEJWhupEZOWTclKJyLx_PZlgwXh258i798S4Nzxfr9rciVTpRSP7v_sNuPv-zDhN0zGb931gxjSTcFvwGCAmQl</recordid><startdate>20190524</startdate><enddate>20190524</enddate><creator>Somda, Sosthene</creator><creator>Lebrun, Amandine</creator><creator>Tranchart, Hadrien</creator><creator>Lamouri, Karima</creator><creator>Prevot, Sophie</creator><creator>Njike-Nakseu, Micheline</creator><creator>Gaillard, Martin</creator><creator>Lainas, Panagiotis</creator><creator>Balian, Axel</creator><creator>Dagher, Ibrahim</creator><creator>Perlemuter, Gabriel</creator><creator>Naveau, Sylvie</creator><creator>Voican, Cosmin Sebastian</creator><general>Public Library of Science</general><scope>IOV</scope><scope>ISR</scope></search><sort><creationdate>20190524</creationdate><title>Adaptation of controlled attenuation parameter</title><author>Somda, Sosthene ; Lebrun, Amandine ; Tranchart, Hadrien ; Lamouri, Karima ; Prevot, Sophie ; Njike-Nakseu, Micheline ; Gaillard, Martin ; Lainas, Panagiotis ; Balian, Axel ; Dagher, Ibrahim ; Perlemuter, Gabriel ; Naveau, Sylvie ; Voican, Cosmin Sebastian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g992-17a178437da3e0921efe6cbad413d031a3615bcad4103312b18ef083e7e8fb153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Algorithms</topic><topic>Analysis</topic><topic>Bariatric surgery</topic><topic>Body mass index</topic><topic>Diagnosis</topic><topic>Fatty liver</topic><topic>Health aspects</topic><topic>Liver</topic><topic>Obesity</topic><topic>Overweight persons</topic><topic>Prevalence studies (Epidemiology)</topic><topic>Risk factors</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Somda, Sosthene</creatorcontrib><creatorcontrib>Lebrun, Amandine</creatorcontrib><creatorcontrib>Tranchart, Hadrien</creatorcontrib><creatorcontrib>Lamouri, Karima</creatorcontrib><creatorcontrib>Prevot, Sophie</creatorcontrib><creatorcontrib>Njike-Nakseu, Micheline</creatorcontrib><creatorcontrib>Gaillard, Martin</creatorcontrib><creatorcontrib>Lainas, Panagiotis</creatorcontrib><creatorcontrib>Balian, Axel</creatorcontrib><creatorcontrib>Dagher, Ibrahim</creatorcontrib><creatorcontrib>Perlemuter, Gabriel</creatorcontrib><creatorcontrib>Naveau, Sylvie</creatorcontrib><creatorcontrib>Voican, Cosmin Sebastian</creatorcontrib><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Somda, Sosthene</au><au>Lebrun, Amandine</au><au>Tranchart, Hadrien</au><au>Lamouri, Karima</au><au>Prevot, Sophie</au><au>Njike-Nakseu, Micheline</au><au>Gaillard, Martin</au><au>Lainas, Panagiotis</au><au>Balian, Axel</au><au>Dagher, Ibrahim</au><au>Perlemuter, Gabriel</au><au>Naveau, Sylvie</au><au>Voican, Cosmin Sebastian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adaptation of controlled attenuation parameter</atitle><jtitle>PloS one</jtitle><date>2019-05-24</date><risdate>2019</risdate><volume>14</volume><issue>5</issue><spage>e0217093</spage><pages>e0217093-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The controlled attenuation parameter (CAP) using FibroScan (Echosens, Paris, France) M or XL probe has been developed for liver steatosis assessment. However, CAP performs poorly in patients with high body mass index. The aim of our study was to assess whether CAP is overestimated using the standard XL probe in patients with morbid obesity, and in the case of an overestimation, to reprocess the data at a greater depth to obtain the appropriate CAP (CAPa). We conducted an observational prospective cohort study on a total of 249 severely obese patients admitted to our institution to undergo sleeve gastrectomy. Patients had a liver biopsy performed during the surgery and a CAP measurement during the 15 days preceding biopsy. Patient files were reprocessed retrospectively by an algorithm, blinded to the patients' clinical data. The algorithm automatically assessed the probe-to-capsula distance (PCD) by analysing the echogenicity of ultrasound signals on the time-motion mode. In the case of a distance &gt;35 mm, the algorithm automatically selected a deeper measurement for CAP (CAPa). When PCD was less than 35 mm, the measured CAP was considered as appropriated (CAPa) and no further reprocessing was performed. CAP recording was not performed at a sufficient depth in 130 patients. In these patients, the CAPa obtained at the adapted depth was significantly lower than CAP (298±3.9 versus 340±4.2 dB/m; p 35 mm, steatosis stage was the only parameter independently correlated with CAP values. For the diagnosis of steatosis (S[greater than or equal to]1), moderate to severe steatosis (S[greater than or equal to]2) and severe steatosis (S = 3), the AUROC curves of CAPa (measured CAP in patients with PCD35 mm) were 0.86, 0.83 and 0.79, respectively. The Obuchowski measure for the diagnosis of steatosis was 0.90±0.013. CAP was overestimated in a half of morbidly obese patients using an XL probe, but CAP can be performed correctly in these patients after adapting the measurement depth.</abstract><pub>Public Library of Science</pub><doi>10.1371/journal.pone.0217093</doi><tpages>e0217093</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2019-05, Vol.14 (5), p.e0217093
issn 1932-6203
1932-6203
language eng
recordid cdi_gale_incontextgauss_ISR_A586555312
source DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry
subjects Algorithms
Analysis
Bariatric surgery
Body mass index
Diagnosis
Fatty liver
Health aspects
Liver
Obesity
Overweight persons
Prevalence studies (Epidemiology)
Risk factors
Surgery
title Adaptation of controlled attenuation parameter
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T11%3A13%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adaptation%20of%20controlled%20attenuation%20parameter&rft.jtitle=PloS%20one&rft.au=Somda,%20Sosthene&rft.date=2019-05-24&rft.volume=14&rft.issue=5&rft.spage=e0217093&rft.pages=e0217093-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0217093&rft_dat=%3Cgale%3EA586555312%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A586555312&rfr_iscdi=true